Patents by Inventor Randal N. Johnston

Randal N. Johnston has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Attenuated reovirus
    Patent number: 10668119
    Abstract: Compositions and methods are provided that relate to an attenuated reovirus exhibiting oncolytic activity toward cancer cells while displaying reduced lytic activity toward non-malignant cells. Exemplified is an attenuated human reovirus derived from persistently infected fibrosarcoma cells that lacks wild-type reovirus S1 and S4 genes and consequently lacks a detectable reoviral outer capsid .sigma.1 protein and expresses a mutated reoviral outer capsid .sigma.3 protein.
    Type: Grant
    Filed: August 24, 2016
    Date of Patent: June 2, 2020
    Assignee: VIROCURE, INC.
    Inventors: Manbok Kim, Randal N. Johnston
  • Attenuated reoviruses for selection of cell populations
    Patent number: 10369171
    Abstract: The present invention relates to methods for killing neoplastic cells, such as ras-activated cancerous cells, in vitro. In particular embodiments, an attenuated reovirus (e.g., a reovirus lacking a wild-type S1 gene) may be administered to a mixed cellular composition comprising cancerous cells and stem cells such as adult stem cells and/or hematopoietic stem cells; in these embodiments, the attenuated reovirus may result in killing of the cancerous cells with little or no damage to the healthy stem cells.
    Type: Grant
    Filed: March 12, 2008
    Date of Patent: August 6, 2019
    Assignee: VIROCURE, INC.
    Inventors: Manbok Kim, Derrick E. Rancourt, Nicole Zur Nieden, Randal N. Johnston
  • Attenuated reovirus
    Patent number: 10260049
    Abstract: Compositions and methods are provided that relate to an attenuated reovirus exhibiting oncolytic activity toward cancer cells while displaying reduced lytic activity toward non-malignant cells. Exemplified is an attenuated human reovirus derived from persistently infected fibrosarcoma cells that lacks wild-type reovirus S1 and S4 genes and consequently lacks a detectable reoviral outer capsid ?1 protein and expresses a mutated reoviral outer capsid ?3 protein.
    Type: Grant
    Filed: July 31, 2006
    Date of Patent: April 16, 2019
    Assignee: VIROCURE, INC.
    Inventors: Manbok Kim, Randal N. Johnston
  • ATTENUATED REOVIRUS
    Publication number: 20170049829
    Abstract: Compositions and methods are provided that relate to an attenuated reovirus exhibiting oncolytic activity toward cancer cells while displaying reduced lytic activity toward non-malignant cells. Exemplified is an attenuated human reovirus derived from persistently infected fibrosarcoma cells that lacks wild-type reovirus S1 and S4 genes and consequently lacks a detectable reoviral outer capsid .sigma.1 protein and expresses a mutated reoviral outer capsid .sigma.3 protein.
    Type: Application
    Filed: August 24, 2016
    Publication date: February 23, 2017
    Applicant: VIROCURE, INC.
    Inventors: Manbok KIM, Randal N. Johnston
  • ATTENUATED REOVIRUS
    Publication number: 20090214479
    Abstract: Compositions and methods are provided that relate to an attenuated reovirus exhibiting oncolytic activity toward cancer cells while displaying reduced lytic activity toward non-malignant cells. Exemplified is an attenuated human reovirus derived from persistently infected fibrosarcoma cells that lacks wild-type reovirus S1 and S4 genes and consequently lacks a detectable reoviral outer capsid ?1 protein and expresses a mutated reoviral outer capsid ?3 protein.
    Type: Application
    Filed: July 31, 2006
    Publication date: August 27, 2009
    Applicants: UNIVERSITY TECHNOLOGIES INTERNATIONAL, INC.
    Inventors: Manbok Kim, Randal N. Johnston
  • Attenuated reoviruses for selection of cell populations
    Publication number: 20090104162
    Abstract: The present invention relates to methods for killing neoplastic cells, such as ras-activated cancerous cells, in vitro. In particular embodiments, an attenuated reovirus (e.g., a reovirus lacking a wild-type S1 gene) may be administered to a mixed cellular composition comprising cancerous cells and stem cells such as adult stem cells and/or hematopoietic stem cells; in these embodiments, the attenuated reovirus may result in killing of the cancerous cells with little or no damage to the healthy stem cells.
    Type: Application
    Filed: March 12, 2008
    Publication date: April 23, 2009
    Inventors: Manbok Kim, Derrick E. Rancourt, Nicole Zur Nieden, Randal N. Johnston
  • Inhibition of viral replication
    Publication number: 20080227688
    Abstract: The present invention provides inhibitors of viral replication, and methods related thereto. In general, such compounds can be classified as peptidyl fluoromethylketones (PFMKs). The PFMK compounds may be used to partially or completely inhibit viral infection. In certain embodiments, Z-FA-FMK may be used to inhibit replication of a reovirus, such as a wild-type or attenuated reovirus, or a leporipoxvirus, such as myxoma virus. These compounds may be useful for controlling viral infectivity in vivo and/or in vitro.
    Type: Application
    Filed: March 13, 2008
    Publication date: September 18, 2008
    Inventors: Randal N. Johnston, Manbok Kim, Morley D. Hollenberg, Kristina K. Hansen